≥99% HPLCPre-filled pen

Retatrutide / Follistatin-344 (Blend)

Name: Retatrutide / Follistatin-344 (Blend)
Brand: Dripfy
Availability: InStock

What it is?

Retatrutide / Follistatin-344 is an investigational blend combining retatrutide, a GLP-1/GIP/glucagon triple receptor agonist currently in active clinical trials and not yet approved, with Follistatin-344, an investigational peptide studied within the myostatin-pathway/muscle research space. The blend brings metabolic and muscle-signalling research angles together.

Dripfy Advantage

Triple incretin signalling: Retatrutide is studied as a single molecule engaging GLP-1, GIP, and glucagon receptors, a metabolic pathway combination under active investigation.
Myostatin-pathway angle: Follistatin-344 is investigated for a proposed role in modulating myostatin signalling relevant to lean mass.
Combined metabolic + muscle focus: The blend is positioned to pair metabolic and muscle-signalling research under one physician-directed protocol.
Physician-directed: Any regimen is determined solely by the supervising physician.

Research & Investigational Focus

Metabolic and weight research: Retatrutide is in active clinical trials for metabolic endpoints; results are still emerging.
Lean-mass and body composition: Follistatin-344 explored preclinically for myostatin-pathway effects on muscle.
Combined metabolic-muscle signalling: The pairing itself is investigational with no robust human data.

Composition & Formulation

Format: Pre-filled pen
Purity: ≥99% by HPLC/MS
Supervision: Physician-directed use only

€506

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

Retatrutide / Follistatin-344 (Blend)

GLP-1/GIP/glucagon tri-agonist + myostatin-pathway peptide blend (investigational) · Pre-filled pen

D· Preliminary evidence

Retatrutide is a single peptide designed to activate GLP-1, GIP, and glucagon receptors simultaneously, a triple-incretin mechanism being studied for metabolic and weight-related endpoints in active clinical trials; it is not yet approved. Follistatin-344 is an investigational peptide proposed to bind and inhibit myostatin, a negative regulator of muscle growth, with evidence largely preclinical. Combining an investigational tri-agonist with a myostatin-pathway peptide is a research hypothesis and has not been characterised in robust human studies.

Studied use areas

Investigated for metabolic and weight-related endpoints (retatrutide, trials ongoing)
Explored for lean-mass and body-composition support (Follistatin-344, preclinical)
Studied for combined metabolic and muscle-signalling pathways
Positioned for research on incretin plus myostatin-pathway interaction

Safety & status

Investigational blend; retatrutide remains in trials and the combination has no robust human safety data
Use only under qualified physician supervision
Incretin agonists are associated with gastrointestinal effects; not for use in pregnancy, breastfeeding, or with a personal/family history of medullary thyroid carcinoma or MEN2

⚕ Clinical note: Retatrutide is still in active clinical trials and is not an approved medicine, and Follistatin-344 is investigational; combining them compounds the uncertainty and has not been validated in robust human studies. This blend is for physician-directed research use only, is not medical advice, and is not proven to treat, cure, or prevent any condition.

Evidence: Grade D — investigational; limited human data, mainly preclinical · References: Jastreboff et al., New England Journal of Medicine 2023; Rosenstock et al., The Lancet 2023; Lee and McPherron, Proceedings of the National Academy of Sciences 2001